Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Conditions
Solid Tumor, Adult · BRCA1 Mutation · BRCA2 Mutation · Ovarian Cancer · Breast Cancer · Prostate Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Chongqing Cancer Hospital, Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Anyang Cancer Hospital, Anyang, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jinan Central Hospital, Jinan, Shandong, China
Qilu Hospital Shangdong University, Jinan, Shandong, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Second Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
First Hospital Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang, China
Study leads
Sherwin Cai, MD
Study Director
Acerand Therapeutics